Programs
Hide
Program registry with workspace ownership, stage progression, and target focus areas. Business and scientific purpose: this view supports faster, evidence-based drug discovery decisions across research, operations, and governance teams. Programs is connected to linked entities, metrics, and workflow actions in this workspace. Use these panels to review evidence, identify risks, and decide the next best scientific action. The view uses deterministic demo data shaped to mirror realistic drug discovery operations.
Program Ownership
| id | name | workspaceId | stage | targetArea |
|---|---|---|---|---|
| PRG-001 | ATLAS-100 | WS-01 | Lead Optimisation | EGFR |
| PRG-002 | KCL-101 | WS-01 | Discovery | Tau |
| PRG-003 | KCL-102 | WS-02 | Preclinical | KRAS |
| PRG-004 | NOVA-103 | WS-02 | Preclinical | KRAS |
| PRG-005 | ATLAS-104 | WS-02 | Preclinical | Tau |
| PRG-006 | KCL-105 | WS-03 | Preclinical | EGFR |
| PRG-007 | ATLAS-106 | WS-02 | Discovery | EGFR |
| PRG-008 | KCL-107 | WS-04 | Discovery | EGFR |
| PRG-009 | NOVA-108 | WS-03 | Discovery | KRAS |
| PRG-010 | NOVA-109 | WS-04 | Lead Optimisation | EGFR |
| PRG-011 | KCL-110 | WS-01 | Preclinical | KRAS |
| PRG-012 | NOVA-111 | WS-04 | Discovery | EGFR |
| PRG-013 | KCL-112 | WS-01 | Discovery | EGFR |
| PRG-014 | ATLAS-113 | WS-01 | Discovery | KRAS |
| PRG-015 | ATLAS-114 | WS-02 | Lead Optimisation | KRAS |
| PRG-016 | KCL-115 | WS-04 | Preclinical | Tau |
| PRG-017 | NOVA-116 | WS-04 | Lead Optimisation | PD-1 |
| PRG-018 | NOVA-117 | WS-02 | Preclinical | IL-6 |
| PRG-019 | NOVA-118 | WS-04 | Discovery | KRAS |
| PRG-020 | ATLAS-119 | WS-02 | Lead Optimisation | PD-1 |
| PRG-021 | ATLAS-120 | WS-04 | Preclinical | EGFR |
| PRG-022 | KCL-121 | WS-01 | Preclinical | PD-1 |
| PRG-023 | ATLAS-122 | WS-02 | Lead Optimisation | EGFR |
| PRG-024 | KCL-123 | WS-03 | Lead Optimisation | Tau |